albendazole (Albenza) (cont.)
PRESCRIBED FOR: Albendazole is FDA approved for the treatment of the following parasitic infections:
DOSING: The dosing of albendazole depends on which parasitic infection is being treated. When treating young children, tablets may be crushed or chewed and swallowed with a drink of water. Patients are advised to take albendazole with food.
Hydatid disease: Patients are treated with albendazole for 28 days followed by a 14 day albendazole free interval, for a total of 3 cycles. Dosing is based on patient weight as follows:
Neurocysticercosis: Treatment duration is 8 to 30 days. Patients are generally prescribed concurrent anticonvulsant (anti-seizure) and corticosteroid therapy during the first week. Dosing is based on patient weight as follows:
Treatment of pediatric patients: doses vary; dose should be determined by a physician with experience treating children with this drug.
DRUG INTERACTIONS: Grapefruit juice may increase in blood levels of albendazole when administered concurrently. Fosphenytoin (Cerebyx) and phenytoin (Dilantin) decrease levels of albendazole by increasing its breakdown.
PREGNANCY: There are no adequate clinical trials of albendazole administration during pregnancy. Albendazole should only be used during pregnancy if the potential benefit of treatment justifies the potential risk to the fetus. Albendazole has been classified FDA as pregnancy risk category C.
Medically Reviewed by a Doctor on 11/21/2014
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index